Pharma News Only (pfe,mrk,wla, sgp, ahp, bmy, lly) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharma News Only (pfe,mrk,wla, sgp, ahp, bmy, lly)

PFE 24.44

-1.7%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mel Spivak who wrote (919)	10/14/1998 12:26:00 PM
From: Anthony Wong	Read Replies (2) of 1722

Mel, this piece of news on LLY from last Sunday may be the reason (but Prozac is old news). Perhaps it's jitters before earnings, now that PFE has disappointed. Nothing so far today. Lilly's 2002 Earnings May Fall on Patent Loss, N.Y. Times Says Bloomberg News October 11, 1998, 2:51 p.m. ET Indianapolis, Oct. 11 (Bloomberg) -- Eli Lilly & Co.'s earnings could fall about 15 percent in 2002 and be unchanged in 2001 if it loses the patent on its top-seller, the antidepressant Prozac, earlier than it expects, the New York Times reported. Lilly expects to keep the patent until at least 2003. Barr Laboratories Inc. is seeking to start sales of a generic Prozac earlier than 2003 and Sepracor Inc. is working on an improved version of the drug, the paper reported. Last week, the U.S. Food and Drug Administration refused to approve expanding the use of Lilly's schizophrenia drug Zyprexa for treatment of bipolar disorder, or manic depression, citing the need for more data. (NYT 10/11 3-1 www.nytimes.com) --Jennifer Farley and Kerry Dooley in the Princeton newsroom

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next